Abbonarsi

Involvement of the CXCR4/CXCL12 axis in skeletal muscle wasting in a murine model of chronic obstructive pulmonary disease (COPD) - 17/02/23

Doi : 10.1016/j.rmr.2022.11.020 
P. Schilfarth 1, 2, , M. Campagnac 2, E. Maurat 2, R. Abohalaka 2, M. Zysman 1, 2, P. Berger 2, 3, I. Dupin 2, P. Henrot 2, 3
1 Service des maladies respiratoires, hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France 
2 Centre de recherche cardiothoracique de Bordeaux, Inserm U1045, PTIB, hôpital Xavier-Arnozan, CHU de Bordeaux, université de Bordeaux, Pessac, France 
3 Service des explorations fonctionnelles respiratoires, hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Riassunto

Introduction

COPD is been increasingly recognised as a systemic disease, where comorbidities play a major role. Among them, conditions affecting the musculoskeletal system such as sarcopenia and osteoporosis, are associated with decreased quality of life and higher mortality [1]. Although the histological abnormalities of sarcopenia are well-characterized, including myofibers atrophy, decreased capillarization and metabolic switch from oxidative phosphorylation to glycolysis, the relative contribution of these processes, as well as the molecular determinants are not fully understood. The expression of both the chemokine receptor CXCR4 and its ligand CXCL12 has been shown to be altered in COPD patients, potentially affecting immune cells recruitment such as neutrophils and fibrocytes [2]. Our goal was to study the implication of the CXCR4/CXCL12 axis in sarcopenia and osteoporosis in a previously validated murine model of COPD.

Methods

C57BL/6 mice were exposed for ten weeks to cigarette smoke (CS) and intranasal instillations of poly-IC to mimick exacerbations. Airway obstruction and peribronchial remodelling was confirmed as previously shown (unpublished data). A conditional inactivation of CXCR4 (CXCR4-/- mice) was also generated via a tamoxifen-inducible Cre/Lox system in CS-exposed mice. Skeletal muscle function was assessed and skeletal muscle tissues were harvested for histological and proteomic analysis. Bone density was evaluated with micro-CT of the proximal region of the tibia in harvested bone samples.

Results

CS-exposed mice displayed no evidence of decreased force or muscular atrophy compared to control mice, but their endurance, assessed by the hanging test, was significantly decreased. CXCR4 deletion attenuated CS-induced muscle dysfunction (Fig. 1A). Histological and proteomic analysis in the quadriceps muscle, composed of both oxidative and glycolytic fibres, showed no difference in the metabolic profile of myofibres between the three groups; however, there was a decreased capillarization in the exposed group, which was reversed in the CXCR4-/- exposed mice. Moreover, analysis of the soleus muscle, exclusively composed of oxidative fibers, showed a metabolic switch from oxidative phosphorylation to glycolysis in the exposed group (Fig. 1B), as well as a tendency to decreased capillarization, which were both reversed in the CXCR4-/- exposed mice. There was no significant difference in bone density between the three groups.

Conclusion

We observed a decreased endurance in an early COPD mouse model, attributed to a metabolic switch of myofibres, and prevented by inactivation of the CXCR4 chemokine receptor. These results provide a framework to study the CXCR4/CXCL12 axis and implicated cells in COPD sarcopenia.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2022  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 40 - N° 2

P. 118 - febbraio 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Exposure to cigarette smoke triggers proteolytic cleavage of occludin, a tight junction protein, by cathepsin S and impairs the pulmonary epithelial barrier during COPD
  • P. Bigot, S. Chesseron, A. Saidi, D. Sizaret, A. Petit-Courty, Y. Courty, F. Lecaille, G. Lalmanach
| Articolo seguente Articolo seguente
  • Expression of pIgR by club cells in human small airways in COPD
  • C. Fays (de), B. Detry, M. Lecocq, V. Geudens, C. Bouzin, S. Gohy, B.M. Vanaudenaerde, C. Pilette

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.